World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 43

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5079)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-4) series.

Item

Count

PDF

196

HTML

2124

Figures (1-6)

380

Tables (1-4)

392

Sum=3092

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

210

Download

831

Sum=1041

Publishing Process of This Article

Item

Count

Browse

116

Download

623

Sum=739

Nov 21, 2024 (publication date) through Mar 9, 2026

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Han RY, Gan LJ, Lang MR, Ren SH, Liu DM, Li GT, Liu YY, Tian XD, Zhu KW, Sun LY, Chen L, Song TQ. Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2024; 30(43): 4620-4635 [PMID: 39575400 DOI: 10.3748/wjg.v30.i43.4620]
URL:	https://www.wjgnet.com/1007-9327/full/v30/i43/4620.htm

Number	Citing Articles
1	Sagnik Biswas, Arghya Samanta. Immune therapies in intermediate-advanced unresectable hepatocellular carcinoma: Changing the therapeutic landscape. World Journal of Gastroenterology 2025; 31(14): 103267 doi: 10.3748/wjg.v31.i14.103267 Abstract(409) \| Core Tip(387) \| Full Article(HTML)(1529) \| Full Article with Cover (PDF)-653K(113) \| Audio-1473K(30) \| Peer-Review Report-251K(82) \| Answering Reviewers-147K(79) \| Full Article (PDF)-370K(137) \| Full Article (XML)-68K(78) \| Times Cited (3) \| Total Visits (4375) \| Open
2	Houxiang Ya, Kai Wang, Huixia Qin, Yi Zhou, Hesheng Lin, Chengyuan Liu, Kaiwen Jiang, Jing Gu, Shuqun Li. Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD‐1 Inhibitor Plus TKIs in Combination of TACE for uHCC. Liver International 2026; 46(3) doi: 10.1111/liv.70551
3	Fei-Yu Zhao, Xiao-Ming Zhang, Nian-Song Qian. Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy. World Journal of Gastroenterology 2025; 31(10): 104429 doi: 10.3748/wjg.v31.i10.104429 Abstract(492) \| Core Tip(423) \| Full Article(HTML)(1380) \| Full Article with Cover (PDF)-621K(160) \| Audio-1658K(24) \| Peer-Review Report-175K(72) \| Answering Reviewers-38K(77) \| Full Article (PDF)-366K(144) \| Full Article (XML)-45K(90) \| Times Cited (0) \| Total Visits (4341) \| Open
4	Ken Sato. Treatment of intermediate-to-advanced unresectable hepatocellular carcinoma is shifting toward a multidisciplinary strategy that includes multiple modalities as needed. World Journal of Gastroenterology 2025; 31(10): 103420 doi: 10.3748/wjg.v31.i10.103420 Abstract(435) \| Core Tip(479) \| Full Article(HTML)(2001) \| Full Article with Cover (PDF)-834K(193) \| Audio-833K(26) \| Peer-Review Report-243K(89) \| Answering Reviewers-100K(90) \| Full Article (PDF)-578K(143) \| Full Article (XML)-91K(87) \| Times Cited (0) \| Total Visits (5363) \| Open
5	Lingbo Hu, Yongfu Xu, Yingli Qiao, Aidong Wang, Caidi He, Rongrong Wang. The effectiveness and safety of immune checkpoint inhibitors in conversion or neoadjuvant therapy for hepatocellular carcinoma: a meta-analysis and systematic review. BMC Cancer 2025; 26(1) doi: 10.1186/s12885-025-15449-2